These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33407715)

  • 1. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
    Vitiello PP; Martini G; Mele L; Giunta EF; De Falco V; Ciardiello D; Belli V; Cardone C; Matrone N; Poliero L; Tirino V; Napolitano S; Della Corte C; Selvaggi F; Papaccio G; Troiani T; Morgillo F; Desiderio V; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2021 Jan; 40(1):15. PubMed ID: 33407715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
    Davis SL; Hartman SJ; Bagby SM; Schlaepfer M; Yacob BW; Tse T; Simmons DM; Diamond JR; Lieu CH; Leal AD; Cadogan EB; Hughes GD; Durant ST; Messersmith WA; Pitts TM
    BMC Cancer; 2022 Oct; 22(1):1107. PubMed ID: 36309653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 4. Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer.
    Zhang N; Tian YN; Zhou LN; Li MZ; Chen HD; Song SS; Huan XJ; Bao XB; Zhang A; Miao ZH; He JX
    Cell Death Dis; 2021 Feb; 12(2):183. PubMed ID: 33589588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    AlHilli MM; Becker MA; Weroha SJ; Flatten KS; Hurley RM; Harrell MI; Oberg AL; Maurer MJ; Hawthorne KM; Hou X; Harrington SC; McKinstry S; Meng XW; Wilcoxen KM; Kalli KR; Swisher EM; Kaufmann SH; Haluska P
    Gynecol Oncol; 2016 Nov; 143(2):379-388. PubMed ID: 27614696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.
    Genther Williams SM; Kuznicki AM; Andrade P; Dolinski BM; Elbi C; O'Hagan RC; Toniatti C
    Cancer Cell Int; 2015; 15(1):14. PubMed ID: 25685067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
    Augustine T; Maitra R; Zhang J; Nayak J; Goel S
    Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
    McKay RR; Morgans AK; Shore ND; Dunshee C; Devgan G; Agarwal N
    Cancer Treat Rev; 2024 May; 126():102726. PubMed ID: 38613872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
    Bridges KA; Toniatti C; Buser CA; Liu H; Buchholz TA; Meyn RE
    Oncotarget; 2014 Jul; 5(13):5076-86. PubMed ID: 24970803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells.
    Sogari A; Rovera E; Grasso G; Mariella E; Reilly NM; Lamba S; Mauri G; Durinikova E; Vitiello PP; Lorenzato A; Avolio M; Piumatti E; Bonoldi E; Aquilano MC; Arena S; Sartore-Bianchi A; Siena S; Trusolino L; Donalisio M; Russo M; Di Nicolantonio F; Lembo D; Bardelli A
    Cell Rep Med; 2024 Feb; 5(2):101376. PubMed ID: 38228147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
    Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C
    Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.
    Ottolino-Perry K; Acuna SA; Angarita FA; Sellers C; Zerhouni S; Tang N; McCart JA
    Mol Oncol; 2015 Oct; 9(8):1539-52. PubMed ID: 26004084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
    Shelton JW; Waxweiler TV; Landry J; Gao H; Xu Y; Wang L; El-Rayes B; Shu HK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):469-76. PubMed ID: 23540347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6.
    Tomicic MT; Steigerwald C; Rasenberger B; Brozovic A; Christmann M
    Arch Toxicol; 2019 Aug; 93(8):2265-2277. PubMed ID: 31289894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
    Zhang N; Gao Y; Zeng Z; Luo Y; Jiang X; Zhang J; Li J; Zhang J; Gong Y; Xie C
    Clin Transl Oncol; 2021 Sep; 23(9):1827-1837. PubMed ID: 33774805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
    Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
    Trials; 2024 May; 25(1):301. PubMed ID: 38702828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
    Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.